| __timestamp | Blueprint Medicines Corporation | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 2999000 |
| Thursday, January 1, 2015 | 14456000 | 10393000 |
| Friday, January 1, 2016 | 19218000 | 15994000 |
| Sunday, January 1, 2017 | 27986000 | 26975000 |
| Monday, January 1, 2018 | 47928000 | 39509000 |
| Tuesday, January 1, 2019 | 96388000 | 48869000 |
| Wednesday, January 1, 2020 | 157743000 | 42510000 |
| Friday, January 1, 2021 | 195293000 | 46105000 |
| Saturday, January 1, 2022 | 237374000 | 50513000 |
| Sunday, January 1, 2023 | 295141000 | 51292000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Wave Life Sciences Ltd. over the past decade. From 2014 to 2023, Blueprint Medicines saw a staggering increase in SG&A expenses, growing nearly 3,640% from approximately $7.9 million to $295 million. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Wave Life Sciences experienced a more modest growth of around 1,610%, with expenses rising from $3 million to $51 million. This difference highlights varying strategic approaches, with Blueprint Medicines focusing heavily on scaling operations. As the biotech sector continues to evolve, these financial insights provide a window into the strategic priorities of these innovative companies.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.
Wave Life Sciences Ltd. and Novavax, Inc.: SG&A Spending Patterns Compared